Financial Performance - Revenue for the three months ended September 30, 2021, was RMB 205,582,000, a decrease of 31.5% compared to RMB 300,142,000 in the same period of 2020[9] - Gross profit for the nine months ended September 30, 2021, was RMB 275,364,000, down 33.2% from RMB 412,367,000 in the corresponding period of 2020[9] - Profit from operations for the three months ended September 30, 2021, was RMB 9,864,000, a decline of 30.5% compared to RMB 14,269,000 in the same period of 2020[11] - Profit before taxation for the nine months ended September 30, 2021, was RMB 34,441,000, a decrease of 5.2% from RMB 36,335,000 in the same period of 2020[11] - The net profit attributable to owners of the Company for the three months ended September 30, 2021, was RMB 5,560,000, down 45.5% from RMB 10,255,000 in the same period of 2020[11] - Earnings per share for the three months ended September 30, 2021, was RMB 0.33, compared to RMB 0.61 in the same period of 2020[11] - Total comprehensive income for the nine months ended September 30, 2021, was RMB 26,661,000, a decrease of 12.5% from RMB 30,491,000 in the same period of 2020[11] - The profit for the period ended September 30, 2021, was RMB 25,207,000, a decrease from RMB 28,505,000 for the same period in 2020, representing a decline of approximately 11.3%[14] Expenses - Selling and distribution expenses for the three months ended September 30, 2021, were RMB 58,961,000, a significant reduction from RMB 128,585,000 in the same period of 2020[9] - Administrative expenses for the nine months ended September 30, 2021, were RMB 55,949,000, an increase from RMB 45,071,000 in the same period of 2020[9] - Other operating expenses amounted to approximately RMB 26,139,000, representing a decrease of approximately 43.64% from approximately RMB 46,378,000 for the corresponding period of last year[88] - Finance costs for the Reporting Period amounted to approximately RMB 2,193,000, representing an increase of approximately 192.40% from approximately RMB 750,000 for the corresponding period of last year[88] - Staff costs for the three months ended September 30, 2021, were RMB 25,940,000, slightly up from RMB 24,835,000 in 2020, indicating a 4.5% increase[59] - Research and development costs for the three months ended September 30, 2021, amounted to RMB 6,699,000, compared to RMB 5,534,000 in 2020, reflecting a growth of 21.0%[59] Revenue Breakdown - Revenue from manufacturing and selling of medicines was RMB 130,547,000, slightly up from RMB 129,468,000 in 2020, representing a 0.8% increase[50] - Revenue from sales and distribution of medicines and healthcare products was RMB 75,035,000, down 56.0% from RMB 170,674,000 in 2020[50] - Total revenue for the nine months ended September 30, 2021, was RMB 596,776,000, a decrease of 21.4% compared to RMB 759,688,000 in the same period of 2020[50] - Other revenue for the nine months ended September 30, 2021, was RMB 21,490,000, an increase from RMB 10,801,000 in the same period of 2020[9] Equity and Reserves - As of September 30, 2021, total equity increased to RMB 942,867,000, up from RMB 887,421,000 as of September 30, 2020, reflecting a growth of approximately 6.2%[14] - The retained earnings as of September 30, 2021, reached RMB 236,109,000, compared to RMB 203,036,000 at the end of the previous year, indicating an increase of about 16.3%[14] - The statutory reserve fund increased to RMB 48,686,000 as of September 30, 2021, compared to RMB 48,465,000 at the beginning of the year, showing a slight increase[14] Financial Position and Liabilities - The company paid dividends of RMB 3,000,000 to non-controlling interests during the reporting period[14] - The total interest expense on financial liabilities not at fair value through profit or loss for the nine months ended September 30, 2021, was RMB 2,193,000, up from RMB 750,000 in 2020, representing a growth of 192.4%[56] - As of September 30, 2021, the Group had no significant contingent liabilities[92] Corporate Governance - The Company has established an Audit Committee to review financial statements and provide suggestions to the Board[132] - The Audit Committee has reviewed the unaudited condensed consolidated results for the Reporting Period[132] - The Company complied with the Corporate Governance Code and Corporate Governance Report requirements under GEM Listing Rules[132] - The Board aims to enhance corporate governance standards to ensure responsible business operations[132] Shareholding Structure - Neptunus Bio-engineering holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[102] - As of September 30, 2021, Neptunus Bio-engineering is the beneficial owner of 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and 70.38% of the Company's issued share capital[110] - The Company has not adopted any share option scheme or granted any options, convertible securities, warrants, or similar rights as of September 30, 2021[104] Compliance and Conduct - Neptunus Bio-engineering confirmed compliance with the Non-Competition Undertakings during the Reporting Period, ensuring no direct or indirect competition with the Company[126] - The Company has adopted a code of conduct regarding securities transactions by Directors, confirming compliance with the required standards during the Reporting Period[127] - The Company is committed to operating its business in an honourable manner[132]
海王英特龙(08329) - 2021 Q3 - 季度财报